StageZero Life Sciences Ltd Total Liabilities
StageZero Life Sciences Ltd total liabilities. Based on the latest financial reports, StageZero Life Sciences Ltd (SZLS) has total liabilities worth CA$11.71 Million CAD (≈ $8.47 Million USD) as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check StageZero Life Sciences Ltd (SZLS) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of StageZero Life Sciences Ltd (1998–2022)
Total liabilities of StageZero Life Sciences Ltd from 1998 to 2022. This chart illustrates how StageZero Life Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data.
StageZero Life Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of StageZero Life Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Social Housing REIT plc
LSE:SOHO
|
UK | GBX266.00 Million |
|
South HARZ Potash Ltd
AU:SHP
|
Australia | AU$1.16 Million |
|
Pasukhas Group Bhd
KLSE:0177
|
Malaysia | RM73.77 Million |
|
Akshar Spintex Limited
NSE:AKSHAR
|
India | Rs112.15 Million |
|
Pensionbee Group PLC
LSE:PBEE
|
UK | GBX5.54 Million |
|
Capricorn Energy PLC
LSE:CNE
|
UK | GBX139.75 Million |
|
Diriteks Dirilis Tekstil Sanayi ve Ticaret AS
IS:DIRIT
|
Turkey | TL13.74 Million |
|
Sentral Mitra Informatika Tbk PT
JK:LUCK
|
Indonesia | Rp22.81 Billion |
Liability Composition Analysis (1998–2022)
This chart breaks down StageZero Life Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see StageZero Life Sciences Ltd asset portfolio.
Liquidity & Leverage Metrics
StageZero Life Sciences Ltd Total Liabilities Ratios Explained
StageZero Life Sciences Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 20.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how StageZero Life Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for StageZero Life Sciences Ltd (1998–2022)
The table below shows the annual total liabilities of StageZero Life Sciences Ltd from 1998 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | CA$8.20 Million ≈ $5.93 Million |
+4.06% |
| 2021-12-31 | CA$7.88 Million ≈ $5.70 Million |
-19.06% |
| 2020-12-31 | CA$9.74 Million ≈ $7.05 Million |
+50.88% |
| 2019-12-31 | CA$6.46 Million ≈ $4.67 Million |
-11.83% |
| 2018-12-31 | CA$7.32 Million ≈ $5.30 Million |
+28.26% |
| 2017-12-31 | CA$5.71 Million ≈ $4.13 Million |
-30.12% |
| 2016-12-31 | CA$8.17 Million ≈ $5.91 Million |
+248.50% |
| 2015-12-31 | CA$2.34 Million ≈ $1.70 Million |
+202.04% |
| 2014-12-31 | CA$776.12K ≈ $561.44K |
-37.93% |
| 2013-12-31 | CA$1.25 Million ≈ $904.54K |
-74.84% |
| 2012-12-31 | CA$4.97 Million ≈ $3.59 Million |
+13.10% |
| 2011-12-31 | CA$4.39 Million ≈ $3.18 Million |
-10.48% |
| 2010-12-31 | CA$4.91 Million ≈ $3.55 Million |
+26.84% |
| 2009-12-31 | CA$3.87 Million ≈ $2.80 Million |
-9.14% |
| 2008-12-31 | CA$4.26 Million ≈ $3.08 Million |
-18.45% |
| 2007-12-31 | CA$5.22 Million ≈ $3.78 Million |
+216.39% |
| 2006-12-31 | CA$1.65 Million ≈ $1.19 Million |
-42.02% |
| 2005-12-31 | CA$2.85 Million ≈ $2.06 Million |
-47.82% |
| 2004-12-31 | CA$5.46 Million ≈ $3.95 Million |
+914.42% |
| 2003-12-31 | CA$537.81K ≈ $389.04K |
+53.92% |
| 2002-12-31 | CA$349.42K ≈ $252.76K |
+118.15% |
| 2001-12-31 | CA$160.17K ≈ $115.87K |
+98.66% |
| 2000-12-31 | CA$80.63K ≈ $58.32K |
+2226.60% |
| 1999-12-31 | CA$3.47K ≈ $2.51K |
+21.33% |
| 1998-12-31 | CA$2.86K ≈ $2.07K |
-- |
About StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more